Skip to main content
Merck's Keytruda approved for 2 bladder cancer indications
5/19/2017
Erik S. Lesser/Getty Images

Merck's Keytruda, or pembrolizumab, has been approved by the FDA as a first-line treatment in patients with locally advanced/metastatic urothelial carcinoma who do not respond to chemotherapy that contains cisplatin. The agency also approved Keytruda as a second-line treatment in patients with advanced/metastatic UC whose disease progressed on or after platinum-containing chemotherapy or within one year of neoadjuvant treatment with the chemotherapy.

Full Story: